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Tuberculosis is a major disease causing every year 1.8 million deaths worldwide and represents the
leading cause of mortality resulting from a bacterial infection. Introduction in the 60’s of ﬁrst-line drug
regimen resulted in the control of the disease and TB was perceived as defeating. However, since the
progression of HIV leading to co-infection with AIDS and the emergence of drug resistant strains, the
need of new anti-tuberculosis drugs was not overstated. However in the past 40 years any new molecule
did succeed in reaching the market. Today, the pipeline of potential new treatments has been fulﬁlled
with several compounds in clinical trials or preclinical development with promising activities against
sensitive and resistant Mycobacterium tuberculosis strains. Compounds as gatiﬂoxacin, moxiﬂoxacin,
metronidazole or linezolid already used against other bacterial infections are currently evaluated in
clinical phases 2 or 3 for treating tuberculosis. In addition, analogues of known TB drugs (PA-824, OPC-
67683, PNU-100480, AZD5847, SQ609, SQ109, DC-159a) and new chemical entities (TMC207, BTZ043,
DNB1, BDM31343) are under development. In this review, we report the chemical synthesis, mode of
action when known, in vitro and in vivo activities and clinical data of all current small molecules targeting
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scoverylille.org1. Introduction
In 2011, tuberculosis (TB) remained the second cause of death
from infectious disease worldwide. It mainly affects the poorest
countries of Africa and Southeast Asia. In 2010, according to the
World Health Organization (WHO), TB incidence and prevalence
were estimated at 8.8 and 12 million cases respectively. 1.1 million
among HIV-negative people and 0.35 million among HIV-positive
people died from TB in the same year [1]. Most importantly, one
third of the world population is infected with latent infection and
10% of those infected people will develop active TB in their life. The
agent responsible for this burden is Mycobacterium tuberculosis.
Bacteria are spread through the air by active TB patients and most
commonly affect the lungs. The major obstacles to the global
control of this infectious disease include the difﬁculties to detect
and cure a sufﬁcient number of cases to interrupt transmission [2].
Several drugs have been developed for controlling TB, curing the
patient and preventing further transmission of the disease. The
directly observed treatment short-course (DOTS), a multidrug
therapy program developed by WHO, is one of the most efﬁcient
weapons against the global TB epidemic. Nevertheless, the treat-
ment success rate struggles to reach the target of 85% [3,4].
Unfortunately, ﬁrst-line treatment can fail due to poor compliance
which leads to the emergence of multidrug resistant (MDR) strains
of M. tuberculosis. In 2010, the number of MDR-TB infections was
estimated at 650,000 cases (5.4% of the global infected population)
[1]. MDR-TB must be treated for 2e4 years with second-line drugs.
These drugs are less effective and often associated with serious side
effects, which reduce patients’ compliance and thus lead to high
rates of recurrence, appearance of extensively drug resistant (XDR)
strains and mortality. In 2010, 58 countries reported at least one
case of XDR-TB. All these data highlight the importance for the
discovery of alternative therapies that could improve treatment of
both sensitive and resistant TB.
Anti-tuberculosis agents in current development trigger a large
panel of biological pathways such as cell wall synthesis, protein
synthesis or membrane energy production [5]. The number of TB
drugs in preclinical and clinical development is today higher than
during the past 40 years. In this article we review all small chemical
entities (MW< 600 g/mol) currently in clinical trials and we brieﬂy
describe some promising strategies that are in preclinical devel-
opment (Fig. 2).
2. Current therapies
Most of the drugs which composed the arsenal of the ﬁrst-line
TB treatment were discovered during the 1950’s and the 60’s
(Fig. 1). In 1944, streptomycinwas the ﬁrst compound used to treat
TB. [6]. This aminoglycoside interferes with protein biosynthesis
through an interaction with the small 30S subunit of the ribosome
[7,8]. The discovery of para-aminosalicylic acid in 1946 was quickly
followed by the important identiﬁcation of isoniazid (INH) [9], one
of the most active anti-TB drug used today. Mechanisms of action
for both compounds were unknown during their development,
and the target of para-aminosalicylic acid is still the subject ofOH
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Fig. 1. Structures of antiinvestigations [10]. Inhibition of mycolic acids biosynthesis, one of
the essential components of the mycobacterial cell wall was
determined as isoniazid mechanism of action [11,12]. Pyr-
azinamide (PZA) appeared as a potential TB drug in 1952 [13]. Its
introduction in the TB treatment in the 1980s was a great success
as it allowed to shorten the duration of the TB therapy from 9 to 6
months. Despite an important similarity of structures between
isoniazid and pyrazinamide, their mechanisms of action are totally
different. Pyrazinamide activity is dependent on pyrazinoic acid
release, which causes intake of proton and dysfunction of the pH
balance of mycobacteria [14,15]. It has been recently shown that
pyrazinoic acid targets the ribosomal protein S1, an essential
protein involved in the ribosome-sparing process of trans-
translation [16].
Ethambutol (EMB) and rifampin (RIF), the two last derivatives
used in the TB ﬁrst-line treatment, were discovered during the 60’s.
Ethambutol is an ethylenediamine discovered in 1961 [17], which
affects the cell wall by speciﬁcally targeting the polymerization of
arabinogalactane and lipoarabinomannane [18]. Finally, rifampin
appeared as a drug of choice for TB treatment [19,20] around 1970,
by acting on replicating and non-replicating mycobacteria. This
derivative belongs to the rifamycine family and inhibits bacterial
RNA synthesis by binding to the b-subunit of the DNA-dependent
polymerase [21].
Despite the efﬁciency of the drugs alone, a signiﬁcant
improvement of the treatment was obtained with combined
therapy in order to limit the apparition of resistant strains. Today,
the current standard regimen (DOTS) for TB recommended byWHO
is a combination of isoniazid, rifampin, ethambutol and pyr-
azinamide for a 6 months therapy.
To treat MDR-TB, WHO recommends the use of second-line
drugs which include aminoglycosides (kanamycin, amikacin), cap-
reomycin, cycloserin, para-aminosalicylic acid, thioamides (ethion-
amide (ETH), prothionamide), and ﬂuoroquinolones (ciproﬂoxacin,
oﬂoxacin, levoﬂoxacin). Ethionamide and prothionamide are
isoniazid analogues discovered in 1956 [22]. As isoniazid, they
target mycolic acids biosynthesis through the inhibition of InhAN
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-tuberculosis drugs.
Fig. 2. Antitubercular compounds in development and their targets.[23]. Isoniazid and the two thioamides analogues are prodrugs that
respectively require bioactivation by two distinct proteins: KatG and
EthA [24e26]. D-cycloserine, another cell wall inhibitor, was
discovered in 1969 [27]. This compound triggers peptidoglycan
synthesis through D-alanine racemase and D-alanine ligase inhibi-
tion [28,29]. In the mean time, aminoglycosid analogues (kana-
mycin, amikacin) [30] and cyclic peptide analogues (viomycin,
capreomycin) of streptomycin were reported. These compounds
target the small subunit 30S of the ribosome [5]. The most recent
anti-TB drugs are ﬂuoroquinolones that derived from nalidixic acid,
discovered in the early 60’s for its antibacterial activity [31]. Among
all the antibacterial ﬂuoroquinolones developed, ciproﬂoxacin,
oﬂoxacin and levoﬂoxacin are the most widely used in anti-TB
treatments [32]. In mycobacteria, ﬂuoroquinolones target the DNA
gyrase, which is the sole type II topoisomerase in this organism
[33e35].
3. Global portfolio of clinical candidates
In this review we present advances that have been made over
the last 10 years, with TB drugs that have entered clinical trials
(Fig. 2). Fluoroquinolones gatiﬂoxacin and moxiﬂoxacin (Phase 3),oxazolidinone linezolid and nitroimidazole metronidazole (Phase
2) have been repurposed for tuberculosis. New chemical entities
have also progressed in clinical development based on optimization
of known chemical scaffolds: this is the case for nitroimidazole
derivatives OPC-67683 and PA-824 both in phase 2, substituted
ethylenediamine SQ109 (phase 2), oxazolidinone analogues PNU-
100480 (phase 2) and AZD5847 (phase 1). Finally, promising dia-
rylquinoline TMC207, ﬁrst compound of a new class of anti-
tuberculosis drugs is currently evaluated in Phase 2. We also
highlight promising strategies currently in preclinical trials that not
only proposed new potent chemical anti-tuberculosis scaffold but
also new biological targets. We discuss every strategy andmolecule
on the basis of their development stage, starting from phase 3 to
end up with preclinical developments.
3.1. Compounds in phase 3 clinical trials: ﬂuoroquinolones
Structure, mode of action and calculated physicoechemical
properties [36] of compounds in phase 3 clinical trials are repor-
ted in Table 1.
The ﬂuoroquinolones gatiﬂoxacin and moxiﬂoxacin (Table 1)
were marketed in 1999 for the treatment of respiratory tract
Table 1
Structures and calculated physicoechemical properties of compounds in phase 3
clinical trials [36].
Name Gatiﬂoxacin Moxiﬂoxacin
Structure
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Family Fluoroquinolone Fluoroquinolone
Mode of action DNA gyrase inhibitor DNA gyrase inhibitor
MW 375.39 401.43
clogP 0.91 0.70
H-bond acc. 7 7
H-bond don. 2 2
PSA 82.11 82.11
Nb rotules 4 4infections. These two molecules are currently in phase 3 clinical
trials for the treatment of TB [37].
3.1.1. Chemical synthesis
The quinolone ring is obtained in a 4-steps procedure from
2,4,5-triﬂuoro-3-methoxybenzoyl chloride (Fig. 3) [38]. The
substitution with the appropriate secondary amine followed by
the hydrolysis of the ethyl ester leads to gatiﬂoxacin and moxi-
ﬂoxacin [39].
3.1.2. Target and mechanism of action
M. tuberculosis does not possess any type IV topoisomerase.
Thus, ﬂuoroquinolones target speciﬁcally the mycobacterial top-
oisomerase II DNA gyrase. This implies that large spectra ﬂuo-
roquinolones suffer from suboptimal inhibition of topoisomerase II
and thus can be improved [35].
3.1.3. In vitro activity against M. tuberculosis
Gatiﬂoxacin and moxiﬂoxacin have better in vitro activity
against M. tuberculosis than the older ﬂuoroquinolones cipro-
ﬂoxacin and oﬂoxacin [40]. MIC against M. tuberculosis H37Rv isCl
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Fig. 3. Synthetic pathways for ga0.12e0.25 mg/mL for gatiﬂoxacin and 0.18e0.5 mg/mL for moxi-
ﬂoxacin [35,41,42]. Gatiﬂoxacin has a slightly better activity against
M. tuberculosis clinical isolates (23 strains) than moxiﬂoxacin.
Indeed, the range of MIC90 is 0.007e0.12 mg/mL for gatiﬂoxacin and
0.031e0.12 mg/mL for moxiﬂoxacin [43].
3.1.4. In vivo efﬁcacy in mice
In a murine model of TB, gatiﬂoxacin (100 mg/kg), moxiﬂoxacin
(100mg/kg) and isoniazid (25mg/kg) had similar activities after a 4
weeks treatment [43]. In mice infected with M. tuberculosis by
inhalation, replacement of isoniazid (25 mg/kg) with moxiﬂoxacin
(100 mg/kg) in the standard RIF/INH/PZA 6 months regimen
shortened the duration of therapy by up to 2months and no relapse
was observed 3 months after the end of the treatment [44].
However this result was not conﬁrmed by Ibrahim and colleagues
in intravenously infectedmice [45]. Substitution of moxiﬂoxacin for
rifampin was deleterious and after 6 months of treatment without
rifampin, mice were still culture positive [46].
In mice intranasally infected, gatiﬂoxacin was evaluated alone
and in addition with ethionamide, pyrazinamide and ethambutol.
The best reduction of the CFU counts in the lungs after 4 weeks of
treatment was obtained with the combination of ethionamide
(75 mg/kg) and gatiﬂoxacin (100 mg/kg) [43].
3.1.5. Phase 1
In healthy volunteers, moxiﬂoxacin and gatiﬂoxacin showed
a high bioavailability (90% and 96% respectively) [47,48]. After
a single oral dose of 400 mg, a maximum plasma concentration
(Cmax) of 4.3 mg/mL for moxiﬂoxacin and 3.4 mg/mL for gatiﬂoxacin
was reached in 1.0 h and 1.5 h, respectively. The half-life was 9.1 h
for moxiﬂoxacin and 6.5 h for gatiﬂoxacin and AUC were respec-
tively 39 and 30 mg h/mL [49].
3.1.6. Phase 2
In TB patients, moxiﬂoxacin and gatiﬂoxacin at 400 mg once
daily have good early bactericidal activities (EBA) from day 0 to day
2 (0.33 and 0.35 log CFU/mL/day respectively) but less than isoni-
azid at 300 mg (0.67 log CFU/mL/day) [50]. Another study showed
that the EBA of a 5 day-monotherapy with moxiﬂoxacin (400 mg
daily) is comparable to that of isoniazid (6 mg/kg once daily) [51].O
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tiﬂoxacin and moxiﬂoxacin.
In a phase 2b study, addition of moxiﬂoxacin to the standard
regimen (RIF/INH/PZA/EMB) in the ﬁrst two months shortened the
time to culture conversion and led to a higher culture conversion
rate after 6 weeks of treatment (82% in the moxiﬂoxacin group
compared to 61% in the standard regimen group) [52]. Substitution
of moxiﬂoxacin for isoniazid in the standard regimen did not
signiﬁcantly increase the culture negativity of patients after 8
weeks of therapy [53]. However replacement of ethambutol with
moxiﬂoxacin or gatiﬂoxacin in the standard regimen signiﬁcantly
improved culture conversion after 8 weeks of treatment and might
shorten tuberculosis therapy [54,55].
3.1.7. Safety and tolerability
Moxiﬂoxacin was safe and well tolerated in a long-term
administration at 400 mg once daily [56]. The main side effects
observed with moxiﬂoxacin and gatiﬂoxacin were headache and
gastrointestinal disturbances [47,48]. No additional adverse events
were observed when ethambutol was replaced with moxiﬂoxacin
or gatiﬂoxacin in the standard regimen [55].
3.1.8. Current advances
Gatiﬂoxacin and moxiﬂoxacin are currently being evaluated in
a phase 3 clinical trials. The aim of these studies is to evaluate the
efﬁcacy and safety of gatiﬂoxacin and moxiﬂoxacin and the possi-
bility of reducing the duration of tuberculosis therapy from six to
four months [57,58].3.2. Compounds in phase 2 clinical trials
Structure, mode of action and calculated physicoechemical
properties [36] of compounds in phase 2 clinical trials are repor-
ted in Table 2.Table 2
Structures and calculated physicoechemical properties of compounds in phase 2 clinical
Name TMC207 PA-824
Structure
Family Diarylquinoline Nitroimida
Mode of action ATP synthase inhibitor Cell wall s
MW 555.50 359.26
clogP 6.93 4.30
H-bond acc. 4 6
H-bond don. 1 0
PSA 45.59 91.33
Nb rotules 8 6
Name SQ109 Linezolid
Structure
Family Diamine derivatives Oxazolidin
Mode of action Cell wall synthesis inhibitor Protein sy
MW 330.55 337.34
clogP 4.94 0.894
H-bond acc. 2 5
H-bond don. 2 1
PSA 24.06 71.1
Nb rotules 9 43.2.1. Diarylquinoline: TMC207
TMC207 (R207910, Bedaquiline) is a novel diarylquinoline
belonging to a new class of anti-tuberculosis drugs (Table 2). This
compound was discovered by Johnson & Johnson through a whole-
cell-screening on Mycobacterium smegmatis and it is currently
clinically developed by Tibotec in collaborationwith the TB alliance.
3.2.1.1. Chemical synthesis. TMC207 is synthesized in ﬁve steps
from 3-phenylpropionic acid and para-bromoaniline. The quinoline
ring is obtained thanks to a VilsmeiereHaack reaction and the ﬁnal
condensation leads to four stereoisomers that are separated by
column chromatography over silica gel and then by chiral chro-
matography to yield the desired (R,S) compound (Fig. 4) [59,60].
3.2.1.2. Target and mechanism of action. TMC207 inhibits the
proton transfer chain of the mycobacterial ATP synthase [61]. The
mechanism of action of the diarylquinolinewas originally proposed
after isolation of mutant strains ofM. tuberculosis andM. smegmatis
that were resistant to TMC207. Their genomes were sequenced and
compared to susceptible strains [62]. The only common mutation
was localized in the atpE gene encoding for subunit c of ATP syn-
thase which was further validated as the compound’s precise target
[63]. TMC207 is not active on human mitochondrial ATP synthase
[64]. Whereas derived from quinolones, TMC207 has no inhibitory
effect on the DNA gyrase of M. tuberculosis.
3.2.1.3. In vitro activity against M. tuberculosis. TMC207 is a potent
agent againstM. tuberculosis H37Rv with a MIC99 equal to 0.030 mg/
mL and against a range of M. tuberculosis clinical isolates with MIC
between 0.030 and 0.120 mg/mL (tested on 6 susceptible strains).
TMC207 has a similar efﬁcacy against sensitive and resistant M.
tuberculosis strains (MIC ¼ 0.003e0.120 mg/mL) [62]. Interestingly,
TMC207 is reported to be active against dormantmycobacteria [65].trials [36].
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Fig. 5. Structure of metronidazole.3.2.1.4. In vivo efﬁcacy in mice. In the nonestablished infection
murine model of TB, a single dose of TMC207 at 50 mg/kg led to
a bacteriostatic effect for 8 days whereas administration of
100 mg/kg resulted in a bactericidal effect for the same period
of time [62]. In the same mouse model, TMC207 (12.5 mg/kg)
was more active than isoniazid (25 mg/kg) after 4 weeks of
treatment.
In the established infection model, TMC207 (25 mg/kg) was
more efﬁcacious than rifampin alone (10 mg/kg) and as active as
the ﬁrst-line regimen (RIF/INH/PZA). Addition of TMC207 (25 mg/
kg) to this regimen improved culture conversion after 4 and 8
weeks of treatment [62]. It was also demonstrated that supple-
mentation of TMC207 (25 mg/kg) to the ﬁrst-line regimen or
substitution of TMC207 for isoniazid in this regimen could shorten
the treatment duration from 6 to 4 months [45]. Indeed mice
treated with these combinations were culture negative after 4
months of therapy and the relapse rate 3 months after the end of
the treatment was similar to that of mice treated for 6 months with
the ﬁrst-line regimen (6%, 13% and 17% respectively). However
TMC207 could not replace rifampin [45].
A combination of TMC207 with the WHO recommended MDR-
TB regimen (amikacin/ETH/MXF/PZA) resulted in negative
cultures in a drug-sensitive mouse model after two months of
treatment [66], whereas without TMC207, 9 months of therapy
were necessary to render both spleens and lungs culture negative
[67]. After 6 months of treatment with the MDR-TB regimen the
relapse rate 3 months after the end of the therapy was 58% and 28%
when TMC207 was added to this regimen [68].
3.2.1.5. Phase 1. Pharmacokinetic study in healthy volunteers
showed that after single oral administrations ranging from 10 to
700 mg, the maximum plasma concentration (Cmax) were reached
at 5 h. Cmax and AUC were proportional to dose at the contrary of
the half-life. The Cmax varied from 0.07 mg/mL for a single oral dose
of 10 mg to 9 mg/mL for a dose of 400 mg. [62]. After once daily
doses for 14 days the AUC0e24h values at steady state were 7.9, 24
and 52 mg h/mL with dose of 50, 150 and 400 mg/day respectively.
CYP3A4 was identiﬁed as responsible for TMC207 oxidative
metabolism and coadministration of rifampin in healthy volunteers
led to a decrease of TMC207 AUC by 50% [69].
3.2.1.6. Phase 2. In an EBA study, recruited patients with drug
susceptible pulmonary TB received once daily oral doses of TMC207
(25 mg, 100 mg or 400 mg) or rifampin (600 mg) or isoniazid
(300 mg) for 7 days. Whereas TMC207 at 25 mg and 100 mg had nobactericidal effect, the decreases of bacterial load in log CFU/mL
from day 0e7 were 0.77 for TMC207 at 400 mg, 1.88 for isoniazid
and 1.70 for rifampin. The bactericidal effect was observed later in
patients treated with 400 mg of TMC207 than in the group
receiving isoniazid or rifampin, however it was of similar magni-
tude on days 4e7 [70].
In a phase 2b study, MDR-TB patients received either TMC207
(400 mg daily for 2 weeks, followed by 200 mg three times
a week) or placebo in combination with 5 second-line drugs. After
8 weeks of treatment, TMC207 increased the proportion of sputum
culture conversion from 9% to 48% [71]. After 24 weeks of treat-
ment, addition of TMC207 resulted in a faster culture conversion
and a higher sputum conversion rate compared to placebo (79% vs
58%) [72].
3.2.1.7. Safety and tolerability. TMC207 was well tolerated. During
the EBA study no serious adverse events occurred [70]. In MDR-TB
patients treated for 2 months with TMC207 the majority of adverse
events were mild to moderate and only nausea occurred more
frequently than in placebo group (26% vs 4%) [71].
3.2.1.8. Current advances. TMC207 is expected to enter phase 3
clinical trial in 2012 to provide early access of TMC207 to patients
with XDR and Pre-XDR-TB [73].
3.2.2. Nitroimidazoles
3.2.2.1. Metronidazole. Metronidazole (Fig. 5), developed in the
1960’s, is currently marketed to treat protozoa and anaerobic
bacteria infections. Because of its preferential activity against
anaerobic organisms [74,75], metronidazole was considered as an
attractive compound to treat non-replicating M. tuberculosis. In
1999 Brooks et al. demonstrated that metronidazole exhibited only
modest activity on in vitro and in vivo models, alone or combined
with isoniazid [76]. Currently, a phase 2 study driven by the
National Institute of Allergy and Infectious Diseases (NIAID) in
South Korea is exploring the impact of adding metronidazole to the
standard second-line drug regimen [77].
3.2.2.2. PA-824. Initially, bicyclic nitroimidazofurans were inves-
tigated as potential radiosensitizing agents for use in cancer
radiotherapy [78] but were also found to display some antituber-
cular activities in both in vitro and in vivo models [79,80]. Very
promising results were obtained for the lead compound of this
chemical series, CGI 17341 (Fig. 6), but associated mutagenicity
discouraged further research with this compound. Nevertheless,
the strong activities obtained with these compounds suggested
that the bicyclic nitroimidazole moiety might be an interesting
pharmacophore. Based on this observation, a chemical library of
328 nitroimidazopyrans [81,82] was designed and evaluated on M.
tuberculosis. One member, PA-824 (Table 2), was identiﬁed as
a promising antitubercular agent.
3.2.2.2.1. Chemical synthesis. The synthesis of PA-824 published
in the original patent, requires 5 linear steps, starting from 2,4-
dinitroimidazole (Fig. 7) which is ﬁrst alkylated on N-1. Then
cyclization affords the nitroimidazopyran fused ring which is con-
verted to PA-824 after alkylation with 1-(bromomethyl)-4-(tri-
ﬂuoromethoxy)benzene [81].
3.2.2.2.2. Target and mechanism of action. PA-824 is bioreduced
by the deazaﬂavin F420 dependent glucose-6-phosphate dehydro-
genase (FGD1) and a deazaﬂavin-dependent nitroreductase Rv3547
(Ddn) [83,84]. PA-824 is active against M. tuberculosis in both
aerobic and hypoxic conditions [82]. Both activities are supposed to
be mediated by two different mechanisms of actions [85]. Stover
et al. [82] showed that PA-824 inhibits the biosynthesis of mycolic
acids in a dose-dependent manner. Singh et al. [85] demonstrated
that activity of PA-824 analogues in anaerobic conditions was
correlated with the formation of the des-nitro metabolite and the
concomitant release of NO. This data was conﬁrmed by a study
published in 2009 by Manjunatha et al. [86] where activity of PA-
824 was comparable to the activity of respiratory poisons like
cyanide. This activity was highlighted by a dramatic drop in intra-
cellular ATP in a dose and time-dependent manner attributed to the
inhibition of cytochrome c oxidase by NO released.
3.2.2.2.3. In vitro activity against M. tuberculosis. The activity of
PA-824 is highly speciﬁc to the M. tuberculosis complex [82]. PA-
824 has similar MIC against drug-sensitive, mono-resistant,
poly-resistant and MDR-TB. The MIC againstM. tuberculosis H37Rv
is 0.039e0.13 mg/mL [82,87e89]. The MIC against drug-sensitive
M. tuberculosis (12 clinical isolates) is 0.06e0.25 mg/mL [82] and
against mono, poly or multidrug resistant M. tuberculosis (21
clinical isolates) the MIC is 0.015e0.531 mg/mL [82,87]. These data
conﬁrm that there is no cross-resistance with other antitubercular
drugs. Under anaerobic conditions, PA-824 showed in vitro
activity comparable to rifampin, moxiﬂoxacin or gatiﬂoxacin [87].
Hu et al. [90] reported that in a Hu/Coates model, PA-824 was
much more active than moxiﬂoxacin against both static and
dormant bacilli.
3.2.2.2.4. In vivo efﬁcacy in mice. In a mouse model of acute TB
infection, PA-824 given orally at 25 mg/kg was as efﬁcient as
isoniazid (25 mg/kg) after 10 days of treatment [82]. In a mouse
model of chronic infection, when administered as single daily dose,
the minimal effective dose (MED) and the minimal bactericidal
dose (MBD) of PA-824 were respectively 12.5 mg/kg and 100 mg/kgNO2N
N
O
Fig. 6. Structure of CGI 17341.[88]. In the initial phase (2 months), PA-824 (100 mg/kg) was as
active as isoniazid (25 mg/kg) and no synergy between PA-824 and
isoniazid was observed. However, this combination decreased
dramatically the selection of INH-resistant mutants. More impor-
tantly, in the 4 months continuation phase (after a 2 month treat-
ment with RIF/INH/PZA), PA-824 (100 mg/kg) exhibited an activity
signiﬁcantly better compared to isoniazid (25 mg/kg) or moxi-
ﬂoxacin (100 mg/kg) and equivalent to the combination RIF/INH
[88]. Nuermberger et al. [91] used RIF/MXF/PZA as a reference
regimen and showed that PA-824 substituted well for rifampin in
a 6 months treatment (2 months with RIF(or PA-824)/MXF/PZA and
4 months with RIF(or PA-824)/MXF). However, addition of PA-824
was unable to shorten the duration of treatment RIF/MXF/PZA
from four months to three months. Finally, Tasnen et al. [92]
showed that in a chronic infection model, the combination RIF/
PA-824 (100 mg/kg)/PZA was more active than the standard
regimen RIF/INH/PZA in both initial and continuation phase. It was
also observed that the activity of PA-824 alone was strikingly
increased when pyrazinamide was added [92].
3.2.2.2.5. In vivo efﬁcacy in guinea pigs. In a chronic infection
model of TB in guinea pigs, similar results were obtained for the
treatment of the infection with PA-824 (40 mg/kg) and isoniazid
(25 mg/kg), after 28 days [82]. Sung et al. [93] reported a dry-
powder aerosol formulation of PA-824 which demonstrated
a high stability (more than 6 months at room temperature and
more than one year at 4 C). Pharmacokinetic parametersmeasured
in guinea pigs were consistent with the previously obtained data.
The inhalation route exhibited a better pharmacokinetic proﬁle
than oral or i.v. administration. However, in a guinea pig model, PA-
824 aerosols showed modest but still encouraging activity
compared to oral administration because of the lower dose absor-
bed by inhalation. Moreover, PA-824 aerosol was more efﬁcient to
prevent formation of granuloma inwhite pulp compared to oral PA-
824 suspension [94].
3.2.2.2.6. Phase 1. In healthy volunteers, after single oral
administrations ranging from 50 to 1500 mg, the Cmax was reached
after 4e5 h and ranged from 0.3 to 2.9 mg/mL. AUC was also dose-
dependent and ranged from 7.5 to 101.8 mg h/mL with a plateau
reached with the dose of 1 g. The mean half-life was around 18 h. In
the 7 days multiple-dose study, steady statewas achieved after 5e6
days for 200 and 600 mg dose groups. To understand a previously
observed increase in serum creatinine during multiple-dose study
[95], an experiment was performed on 47 healthy patients in order
to evaluate effect of PA-824 on their renal function. PA-824 up to
1 g/day for 8 days was shown to be safe and well tolerated [96].
3.2.2.2.7. Phase 2. A randomized study [97] with 69 drug-
sensitive, smear-positive pulmonary TB patients showed that the
use of four doses (200 mg, 600 mg, 1000 mg, 1200 mg) led to the
same EBA of 0.1 log CFU/day/mL. These results suggested that the
parameter which drives the EBA was the time above MIC rather
than the ratios AUC/MIC or Cmax/MIC. This hypothesis has been
conﬁrmed recently in a mouse model [89].
Two new EBA experiments with PA-824 alone or in combination
with known antitubercular drugs are ongoing [98].
3.2.2.3. OPC-67683. OPC-67683 (Delamanid, Table 2) was designed
from CGI 17341 (Fig. 6) with the objective to enhance its TB-activity
and to lower its toxicity [99].
3.2.2.3.1. Chemical synthesis. The chemical synthesis of OPC-
67683 is based on a convergent strategy described in Fig. 8 [99].
The ﬁrst synthon is obtained by a Buchwald palladium-catalyzed
arylation of 4-(4-(triﬂuoromethoxy)phenoxy)piperidine. Then
the removal of the tetrahydropyran protecting group affords
the desired phenol. The second synthon is prepared from 2-chloro-
4-nitroimidazole which is mono-alkylated with an epoxide.
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Fig. 7. Synthetic pathway for PA-824.De-esteriﬁcation of the product gives a diol which is converted to
an epoxide after selective mesylation and cyclization. Coupling
of the two synthons followed by intramolecular ring-closure leads
to OPC-67683.
3.2.2.3.2. Target and mechanism of action. OPC-67683 is a struc-
turally close analogue of PA-824 and it inhibits methoxy-mycolic
and keto-mycolic acids biosynthesis with IC50 values respectively
equal to 0.036 mg/mL and 0.021 mg/mL. Moreover, as observed for
PA-824, deazaﬂavin-dependent nitroreductase bioreduces OPC-
67683 into the corresponding des-nitro metabolite [100].
3.2.2.3.3. In vitro activity against M. tuberculosis. MIC ranging
from 0.006 to 0.0134 mg/mL were measured against both drug-
sensitive and drug resistant strains (more than 70 strains) [100].
No antagonistic activity of OPC-67683 was observed when
combined with rifampin, isoniazid, ethambutol and streptomycin.
OPC-67683 was very potent on intracellular M. tuberculosis: atFig. 8. Synthetic pathw0.1 mg/mL it was as active as rifampin at 3 mg/mL and more active
than isoniazid and PA-824 at 3 and 1 mg/mL respectively.
3.2.2.3.4. In vivo efﬁcacy in mice. In a mouse model of chronic
tuberculosis, a reduction of 95% in CFU count was obtained with
OPC-67683 at a dose of 0.625mg/kg whereas 3.5, 5, 40 and 160 mg/
kg of respectively rifampin, isoniazid, pyrazinamide and strepto-
mycin were needed to achieve the same activity [100]. Similar
activities were recorded in immunocompetent or immunocom-
promised BALB/c mice. The combination OPC-67683 (2.5 mg/kg)/
RIF (5 mg/kg)/PZA (100 mg/kg) was found to be much more active
than the standard regimen RIF (5 mg/kg)/PZA (100 mg/kg)/INH
(10 mg/kg)/EMB (100 mg/kg).
3.2.2.3.5. Pharmacokinetics. In M. tuberculosis infected mice
model, OPC-67683 at a dose of 2.5 mg/kg reached after 6 h a Cmax of
0.297 mg/mL. An AUC of 4.13 mg h/mL and a half-life of 7.6 h were
measured [100]. OPC-67683 is not a substrate of human CYPay for OPC-67683.
enzymes, and it has neither inhibitory nor inductive effect on CYP
at concentrations up to 100 mM [100].
In smear-positive pulmonary TB patients [101], in a 14 days
multiple-dose study, Cmax and AUC0e24h overlapped across dosages
and reached a plateau at 300 mg, certainly due to poor absorption.
For all patients, tmax ranged from 4 to 5 h. At all dosages OPC-67683
was well tolerated and did not exhibit any toxicity.
3.2.2.3.6. Phase 2. An EBA study was conducted in 48 patients
with smear-positive TB, receiving 100, 200, 300 or 400 mg of
OPC-67683 daily during 14 days [101]. Albeit no signiﬁcant
differences between the four dosages were observed (an average
EBA of 0.040 log CFU/mL/day was measured) the frequency of
patients presenting a better response with 200 mg and 300 mg
was noticed.
A second phase 2 study has already been completed and one is
ongoing [102]. The aim of these studies is to evaluate the efﬁcacy,
safety and pharmacokinetics of OPC-67683 in patients with
pulmonary MDR-TB.
3.2.3. Diamine derivative: SQ109
SQ109 (Table 2) is a synthetic analogue of ethambutol [103]. It
was discovered from a focused library of ethylenediamine
analogues containing 63,238 compounds [104].
3.2.3.1. Chemical synthesis. The solution phase organic synthesis
of SQ109 is described in Fig. 9. Transetrans farnesyl bromide is
substituted by ethylenediamine to yield the corresponding
monosubstituted amine. Reductive amination performed with
2-adamantanone yields the desired 2-adamantyldiamine SQ109
[105].
3.2.3.2. Target and mechanism of action. The exact mechanism of
action of SQ109 is not yet known. SQ109, as ethambutol, was shown
to over-produce the ATP-dependent DNA/RNA helicase and to
reduce the production of the b-ketoacyl-acyl carrier protein syn-
thase which may explain its action on mycobacterial cell wall
synthesis [106]. Interestingly, SQ109 is still active against EMB-
resistant strains, therefore SQ109 is believed to act in a different
manner than ethambutol [103]. It was also shown that SQ109 is
active against RIF-resistant strains [107].
3.2.3.3. In vitro activity against M. tuberculosis. SQ109MIC reported
in the literature ranges from 0.63 mM [104] to 1.56 [103] on drug-
sensitive strains, is equal to 0.9 mM on EMB-resistant strain,
1.4 mM on INH-resistant strain and 0.7 mM on RIF-resistant strain
[103]. Recently, SQ109 and TMC207 have been studied in combi-
nation on M. tuberculosis H37Rv culture. Activity of TMC207 was
improved by 4- to 8-fold in the presence of SQ109. Moreover, theBr
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NH2
O
MeOH
NaBH4
DCM
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2/ 
Fig. 9. Synthetic pathrate of killing bacteria was higher in combination than for drugs
alone [108]. SQ109 also showed synergistic effect with antituber-
cular drugs isoniazid and rifampin [107].
3.2.3.4. In vivo efﬁcacy in mice. SQ109 was shown more effective
than ethambutol in vivo. In a chronic mouse model of TB, SQ109 at
10 mg/kg and 25 mg/kg was able to reduce the number of lung CFU
and spleen CFU respectively by 1.5e2.5 log after 30 days of treat-
ment, activity that was similar to monotherapy with ethambutol at
100 mg/kg [103]. In vivo studies in the same model showed that
substitution of SQ109 (10 mg/kg) for ethambutol (100 mg/kg)
improved efﬁcacy of ﬁrst-line drug therapy combination after 4 or 8
weeks of treatment [109].
3.2.3.5. Pharmacokinetics. In mouse, oral administration of 10 mg/
kg for 28 days resulted in a plasma concentration equivalent to 10
times the MIC. However, oral bioavailability of SQ109 was low (8%)
and in general, SQ109 concentrations were higher in organs than in
plasma. SQ109 plasma concentration-time course after single oral
administration (25mg/kg) tomicewas 0.254 mg h/mL, and Cmax and
Tmax were respectively 0.135 mg/mL and 0.31 h [110]. SQ109 was
shown to be oxidized and N-dealkylated, predominantly involving
the human CYP2D6 and CYP2C19 [111].
3.2.3.6. Phase 1. SQ109 has completed three phase 1 studies in the
USA. A phase 1 double-blind, placebo-controlled study performed
on 62 healthy adults showed that oral doses of SQ109 up to 300 mg
were safe and well tolerated. SQ109 was rapidly distributed to
tissues and presented a long half-life of 61 h [112]. In 2007, the U.S.
Food and Drug Administration (FDA) and the European Medicines
Agency (EMEA) granted SQ109 orphan drug status for the treat-
ment of TB. Another phase 1 has been completed in 2009. This
study was performed to determine safety and pharmacokinetics of
multiple-doses of SQ109 in healthy volunteers. Results are not yet
published. SQ109 is currently being evaluated in a phase 2a trial in
adults with smear-positive pulmonary TB [113].
3.2.4. Oxazolidinones
3.2.4.1. Linezolid. Linezolid (Table 2) was introduced in the USA for
the treatment of patients with infections caused by Gram-positive
pathogens (Staphylococci, Streptococci and Entercocci) responsible
for skin and soft tissue infections, pneumonias and bacteraemias
[114]. Linezolid is used for courses of treatment up to 28 days. This
compound belongs to the (S)-oxazolidin-2-one family class of
compounds and is a direct analogue of DuP105 and DuP721 (Fig. 10)
described to have MIC of 0.3e1.25 mg/mL against M. tuberculosis
[80] and which development was discontinued in Phase 1 due to
toxicity issues.N
H
NH2
N
H
N
H
way for SQ109.
3.2.4.1.1. Chemical synthesis. The synthesis of linezolid at the
process scale is described in Fig.11 [115]. N-carbobenzoxy-3-ﬂuoro-
4-morpholinylaniline is synthesized from commercially available
3,4-diﬂuoro-nitrobenzene by nucleophilic aromatic displacement
with morpholine, followed by reduction and functionalization of
the resulting amine in benzyl carbamate. Nitrogen deprotonation is
obtained with lithium t-amylate and substitution of S-(þ)-3-
chloro-1,2-propanediol is followed by cyclization into oxazolidi-
none. Primary alcohol is then reacted with 3-nitrobenzenesulfonyl
chloride and treated with aqueous ammonium hydroxide to give
the corresponding primary amine. Following acylation to yield
linezolid is performed with acetic anhydride [116].
3.2.4.1.2. Target and mechanism of action. Linezolid presents
a unique mechanism of action which was supported by the lack of
cross-resistance between oxazolidinones and other antibiotics. It
binds to the 23S RNA in the 50S ribosomal subunit and limits the
growth of bacteria by disrupting its production of proteins in the
ﬁrst step of the synthesis by inhibiting formation of the initiation
complex [117].
3.2.4.1.3. In vitro activity against M. tuberculosis. Linezolid has
a high in vitro antibacterial activity (MIC of 0.125e0.5 mg/mL)
against M. tuberculosis [114,118e120].
3.2.4.1.4. In vivo efﬁcacy in mice. In an acute mouse model of
infection, linezolid given at 100mg/kg, one day after infection and 5
days a week for four weeks was able to reduce bacterial growth in
spleen and lung, unfortunately in a less efﬁcient manner than
isoniazid (25 mg/kg) [121].
3.2.4.1.5. Clinical phases. Only few Phase 1 and 2 clinical data
have been published so far. EBA and extended EBA of linezolid has
been studied in patients with pulmonary TB [122]. Linezolid at
600 mg/day presented weak early and extended bactericidal
activities when given once or twice daily to patients with pulmo-
nary TB [122]. Efﬁcacy of linezolid to treat MDR-TB in combination
regimens was assessed in two studies with a total of 11 patients
[123,124]. Doses of 600 and 1200 mg/day allowed sputum and
cultures to become negatives and some patients were cured after
treatment. However toxic side effects such as peripheral and optic
neuropathy were common. Today linezolid is used off-label as
a third-line agent in combination regimens to treat MDR-TB or
XDR-TB [125].
3.2.4.2. PNU-100480. As discussed previously, the use of linezolid
is limited by adverse effects that occur with long-term adminis-
trations. Therefore, new analogues showing identical or better
in vivo activities and a better therapeutic indexwould be useful. The
development of PNU-100480 (Sutezolid, Table 2), a close structural
analogue of linezolid was initiated by Upjohn.
3.2.4.2.1. Chemical synthesis. With the exception of morpholine
that was replaced by a thiomorpholine, the synthesis procedure of
PNU-100480 is closely parallel to the one of linezolid (Fig. 11).
3.2.4.2.2. In vitro activity against M. tuberculosis. PNU-100480
exhibits a MIC range of 0.03e0.50 mg/mL against a panel of 5
sensitive and 5 drug resistant strains of M. tuberculosis, which
makes it, in average, 3.2 times more efﬁcient than linezolid
[118,126]. Its sulfoxide and sulfone metabolites (PNU-101603 and
PNU-101244) was shown to contribute to its activity.N O
O
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O
S
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Fig. 10. Structures of oxazolidinone derivatives DuP105 and DuP721.3.2.4.2.3. In vivo efﬁcacy in mice. PNU-100480 is more
potent than linezolid in the mouse model and its potency was
comparable to isoniazid [121,127]. Moreover, PNU-100480 signiﬁ-
cantly improves the initial bactericidal activity of several combi-
nations of existing ﬁrst-line drugs [128].
3.2.4.2.4. Phase 1. Trials with PNU-100480 have been completed
[129] and published [130,131]. These studies were designed
to assess safety, tolerability, pharmacokinetics and for the ﬁrst
time mycobactericidal activities, measured in ex-vivo whole-blood
culture, of single or multiple ascending doses of PNU-100480. In
both studies, doses up to 1200 mg/day were well tolerated; expo-
sure increased linearlywith dose and antimycobacterial activitywas
superior to linezolid. No haematologic safety signals in healthy
volunteers were observed with optimal dose of PNU-100480:
600 mg twice daily for 28 days. In the multiple-dose study, syn-
ergestic effect with PZA was observed. A phase 2a to assess EBA of
PNU-100480 is ongoing [132].3.3. Compound in phase 1 clinical trials: oxazolidinone AZD5847
Structure, mode of action and calculated physicoechemical
properties [36] of AZD5847 in phase 1 clinical trials are reported
in Table 3.
New oxazolidinone derivative, AZD5847 (also known as
AZD2563) currently in phase 1 clinical trials (Table 3), is developed
by AstraZeneca. Two studies, a single ascending dose and multiple
ascending dose over 14 days, have now been completed for
AZD5847 [133]. Bioavailability in fasted volunteers was reported to
decrease with increasing doses, declining from 100% at 50 mg to
less than 30% at 1200 mg. However, this tendency was corrected by
food intake. AZD5847 was tolerated over 14 days in healthy
volunteers. The doses selected for investigation in phase 2 studies
are 500 mg once and twice daily, 800 mg twice daily and 1200 mg
once daily and will be compared to Rifafour (RIF/INH/PZA/EMB) 1
pill per os once daily [134]. A phase 2a is scheduled to start in 2012.3.4. Compounds in preclinical development
Structure, mode of action and calculated physicoechemical
properties [36] of compounds in preclinical development are
reported in Table 4.
3.4.1. Fluoroquinolone: DC-159a
As moxiﬂoxacin and gatiﬂoxacin, DC-159a (Table 4) belongs to
a new generation of ﬂuoroquinolones.
3.4.1.1. Target and mechanism of action. Themechanism of action of
DC-159a is still under investigation, but as other quinolone deriv-
atives, DC-159a probably affects GyrA activity, which plays impor-
tant roles in DNA replication [135,136]. However DC-159a-resistant
mutants revealed patterns of mutations in GyrA different than the
ones observed in quinolones-resistant strains [137]. DC-159a
showed better in vitro and in vivo activities against quinolone
resistant multidrug resistant tuberculosis strains (QR-MDR-TB)
than some other ﬂuoroquinolones [137]. Therefore, it has been
proposed that DC-159a may be a replacement drug for the treat-
ment of QR-MDR cases.
3.4.1.2. In vitro activity against M. tuberculosis. DC-159a showed
MIC90 of 0.06 mg/mL against drug susceptible strains (n ¼ 21) and
0.5 mg/mL against QR-MDR strains (n ¼ 11) [138]. In that study, DC-
159a was 4e32 fold more active than the three classic quinolone
drugs levoﬂoxacin, gatiﬂoxacin and moxiﬂoxacin.
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Fig. 11. Synthetic pathway for linezolid.3.4.1.3. Pharmacokinetics. Single oral administrations ranging from
37.5 to 150 mg/kg showed a dose-dependent response in a murine
TB model. At 100 mg/kg the DC-159a exposure in serum (AUC0eN:
14.7 mg h/mL; Cmax: 10.3 mg/mL) was comparable to that observed
for moxiﬂoxacin [139,140]. Furthemore, the concentration of DC-
159a in lungs of mice were approximately 4 times greater than
that of serum at all doses. The half-life was observed at 1.51 h in
serum and 1.93 h in lungs after a 100mg/kg administration [139]. In
a monkey model, slightly better pharmacokinetic properties
(AUC0e24: 16.9 mg h/mL; Cmax: 2.20 mg/mL) were found for DC-159a
at 5 mg/kg compare to levoﬂoxacine [138].
3.4.1.4. In vivo efﬁcacy in mice. In M. tuberculosis H37Rv infected
mice, during the initial phase of treatment (2 months), the activity
of DC-159a alone (25 mg/kg) was superior to moxiﬂoxacin at
25 mg/kg and equivalent to moxiﬂoxacin at 50 mg/kg [140]. During
the 2 months continuation phase (after a 2 months treatment with
RIF/INH/PZA), DC-159a at 100 mg/kg displayed the same bacteri-
cidal activity as isoniazid (10 mg/kg) and a statistically superior
activity to moxiﬂoxacin at 100 mg/kg [140]. EBA of DC-159a was
evaluated in mice with a drug susceptible M. tuberculosis infection
model [139]. At 100 mg/kg DC-159a exhibited the best EBA at 3, 6
and 9 days of treatment, compared to moxiﬂoxacin (100 mg/kg),
levoﬂoxacine (100 mg/kg), isoniazid (10 mg/kg) and rifampin
(20mg/kg). Unlike moxiﬂoxacin, DC-159a enhanced its activity (log
reduction of CFU in lungs) continuously from day 3e9. After 9 days
of treatment, DC-159a (50 mg/kg), isoniazid (10 mg/kg) and
rifampin (20 mg/kg) demonstrated an equivalent activity. The
efﬁcacy of DC-159a was evaluated in lungs of mice infected by QR-
MDR-TB after two weeks of treatment [139]. DC-159a at 100 mg/kgTable 3
Structure and calculated physicoechemical properties of AZD5847 in phase 1 clin-
ical trials [36].
Name AZD5847
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Family Oxazolidinone
Mode of action Protein synthesis inhibitor
MW 465.4
clogP 1.44
H-bond acc. 7
H-bond don. 2
PSA 125.6
Nb rotules 7signiﬁcantly inhibited M. tuberculosis growth in lungs (2 log CFU
reduction). In the same study, treatment of QR-MDR-TB infected
mice with 50, 75 and 100 mg/kg of DC-159a, recorded notable
superior mean survival compared to untreated control and to
moxiﬂoxacin (100 mg/kg), levoﬂoxacin (100 mg/kg), rifampin
(20 mg/kg) or isoniazid (10 mg/kg) treatments. Additional
preclinical studies are currently in progress.
3.4.2. Diamine derivative: SQ609
While SQ109 was under development, several new dipiperidine
analogues were designed and they demonstrated activity against
M. tuberculosis [141]. The solid-phase synthesis and screening of
a focused library of 10,358 diamines led to the discovery of dipi-
peridine analogue SQ609 (Table 4). In M. tuberculosis infected
macrophages in vitro, a concentration of 4 mg/mL of SQ609 was able
to inhibit 90% of bacterial growth without showing any toxic effect.
In vivo efﬁcacy of SQ609 was evaluated in M. tuberculosis H37Rv
infected mice. C3H/He mice intravenously infected were treated
once daily with SQ609 at 10 mg/kg for 2 weeks. SQ609 was shown
to prevent weight loss of the animals and was able to prolong
therapeutic effect 2 weeks after the end of the treatment [142].
SQ609 is currently being evaluated in preclinical studies.
3.4.3. Nitrophenyl derivatives
3.4.3.1. BTZ043. A new class of sulphur containing heterocyclic
called benzothiazinones (BTZ) has been recently described as
potent antimycobacterial agents [143]. The structureeactivity
relationships study showed that sulphur atom and one or two
nitro groups on the aromatic structure were required to inhibit
bacterial growth in vitro. Compound BTZ038 (Table 4), was themost
active of the series (Fig. 12).
3.4.3.1.1. Chemical synthesis. The synthesis of BTZ038 is
described in Fig. 12. A 25% aqueous solution of ammonia is added to
a solution of 2-chloro-3-nitro-5-triﬂuoromethylbenzoyl chloride in
acetonitrile to give 2-chloro-3-nitro-5-(triﬂuoromethyl)benza-
mide. The benzamide intermediate is treated with 1,4-dioxa-8-
azaspiro[4.5]decane-8-carbodithioic acid sodium salt, obtained
from4-piperidone [144], to yield substituted intermediate, which is
cyclized in aqueous ethanolic solution. BTZ038 is obtained as
crystalline solid after recrystallization [145].
3.4.3.1.2. In vitro and in vivo efﬁcacy. Compound BTZ038
contains one stereogenic center and both S (BTZ043) and R
(BTZ044) enantiomers were tested separately and were shown to
be equipotent with MIC against M. tuberculosis and M. smegmatis
respectively equal to 1 and 4 ng/mL. Similar activities on a panel
of MDR and XDR strains [146] indicated that this new family was
acting on a new target. Two independent genetic approaches
were applied to ﬁnd the target of BTZ043. A decap-
renylphosphoryl-beta-D-ribose 20-epimerase called DprE1
(Rv3790) was validated as the BTZ043 target. It catalyses the
Table 4
Structures and calculated physicoechemical properties of compounds in preclinical development [36].
Name DC-159a SQ609 BDM31343
Structure N N
O
OH
O
O
F
NH F
NNOH
S N O
N
N
O
CN
Family Fluoroquinolone Diamine derivatives 1,2,4-oxadiazole
Mode of action DNA gyrase inhibitor Cell wall synthesis inhibitor EthR inhibitor
MW 419.42 332.52 302.35
clogP 0.87 2.34 1.38
H-bond acc. 7 3 4
H-bond don. 2 1 0
PSA 96.1 26.71 111.26
Nb rotules 4 3 3
Name BTZ043 DNB1
Structure
O
O
S
N
O
CF3
NO2
N
O N
NO
N
H
O
O
OMe
Family Nitrophenyl derivatives Nitrophenyl derivatives
Mode of action DprE1 inhibitor DprE1 inhibitor
MW 431.39 361.31
clogP 3.51 2.44
H-bond acc. 8 7
H-bond don. 0 1
PSA 122.24 139.19
Nb rotules 3 8epimerization of decaprenylphosphoryl ribose to decap-
renylphosphoryl arabinose, a precursor of arabinan synthesis,
which is essential for cell wall synthesis [143]. Further metabolic
studies indicated that BTZ043 is a prodrug and its mycobacterial
reduction, leads to a nitroso derivative that covalently binds to
Cys387 of DprE1 [143]. NfnB, a mycobacterial nitroreductase, was
shown to contribute to the reduction of BTZ043 [147]. In vivo
efﬁcacy was assessed with BTZ043 in a mouse infection model.
BALB/c mice were infected with a low bacillary load of M.
tuberculosis H37Rv via aerosol then treated by gavage for 4 weeks
with BTZ043 at 37.5 and 300 mg/kg. Compound was suspended
in carboxymethyl cellulose (0.25%) and given once daily, six times
a week. The Cmax and AUC were measured and were found to beO
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Fig. 12. Synthetic pathequal respectively to 2 mg/mL and 4.6 mg h/mL. Reduction of
bacterial burden in lungs and spleen was respectively equal to 1
and 2 logs of CFU at the highest dose. BTZ043 is still evaluated in
preclinical development.
3.4.3.2. DNB1. Dinitrobenzamide analogues as DNB1 (Table 4)
were recently identiﬁed thanks to a phenotypic cell-based assay
that uses automated confocal ﬂuorescence microscopy [148,149].
They showed high activity against sensitive and XDR M.
tuberculosis strains. These derivatives were also shown to inhibit
decaprenylphospho-arabinose synthesis by targeting decaprenyl-
phosphoribose 20 epimerase DprE1 and are currently under
development.O
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Fig. 13. Synthetic pathway for BDM31343.3.4.4. 1,2,4-Oxadiazole derivative: BDM31343
Many antituberculous agents are prodrugs. Among them, the
second-line drug ethionamide is activated by a mycobacterial
mono-oxygenase called EthA. The expression of ethA and thus the
potency of the drug are limited by the transcriptional repressor
EthR [26]. In vitro overproduction of EthR was shown to confer
resistance to ethionamide whereas EthA overproduction via ethR
KO conferred at least a 25-fold increase of ethionamide potency
[150]. A new concept emerged from this observation and drug-like
inhibitors of EthR were designed and validated as boosters of
ethionamide activity in order to improve therapeutic index of this
antibiotic [151,152].
Hit compound BDM14500 (Fig. 13) was identiﬁed thanks to
a functional screening of a focused library. BDM14500 was vali-
dated in vitro for its capacity to boost the antimycobacterial activity
of ethionamide. BDM14500 was in the same time cocrystallized
with EthR and revealed to occupy as expected the ligand binding
domain of the protein. Optimization process led to the discovery of
BDM31343 (Table 4) that proved to be 10-fold more active, more
soluble in aqueous solution and more stable in mouse liver
microsomes [151].
3.4.4.1. Chemical synthesis. BDM31343 is synthesized in four steps
from thiophene-2-carbonitrile. 1,2,4-oxadiazole ring synthesis is
performed in DMF after acylation of 2-thiopheneamidoxime with
Boc-isonipecotic acid. Finally, deprotection and acylation of piper-
idine with cyanoacetic acid yield the desired product (Fig. 13) [151].
3.4.4.2. In vivo efﬁcacy in mice. At 100 mg/kg, BDM31343 did not
show any sign of toxicity and presented a mice exposure suitable
for in vivo evaluation (AUC ¼ 82 mg h/mL). The capacity of
BDM31343 to reduce the mycobacterial load synergistically with
ethionamide was evaluated in TB infected mice. Coadministration
of ethionamide (3mg/kg) and BDM31343 (50mg/kg, twice daily via
intraperitoneal administration) during 3 weeks reduced the
bacterial load all over the treatment as efﬁciently as a dose of 9 mg/
kg of ethionamide administered alone [151]. Thus BDM31343 was
able to triple the activity of ethionamide in mice. Distribution study
of BDM31343 in mouse using MALDI imaging revealed that the
compound is localized in brain, lungs, liver and intestine [153].
Optimization of this 1,2,4-oxadiazole series led to the identiﬁcation
of more potent analogues showing a better pharmacokinetic proﬁle
[154,155]. Compounds are currently further evaluated in preclinical
studies.4. Conclusion
For the ﬁrst time in 40 years, a large number of consortia and
pharmaceutical companies have exhibited massive drug discovery
efforts to develop new chemical series using either target-based or
phenotypic screens. There are at least ten compounds in clinical
trials and strategies for the development of new molecules are
ready to fuel the pipeline. Most of them are still in preclinical
testing but one might expect a candidate to rapidly reach the clinic.
New targets have been identiﬁed and validated with drug-like
molecules and the most advanced compound TMC207 might
open a bright avenue for the TB treatment. Number of pharma-
ceutical companies involved in TB drug development projects has
also increased. However, drug development is a long process
especially for TB and it is likely that only one or two new drugs will
arrive on the market from these efforts. Bacterial resistance and
thus requirement for combinations of molecules tend to suggest
that the current development pipeline is not yet sufﬁciently
backed-up to overcome the major unmet medical needs in TB
treatment. Efforts are still eagerly needed if we want to have soon
a chance to win the battle against this millenary scourge.References
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